Davipharm

As Davipharm celebrates its 20th anniversary, the company stands as a beacon of high quality in the pharmaceutical industry. Over two decades, Davipharm has evolved from a local pharmaceutical entity into a progressive and internationally recognized company as a member of Adamed Group. This remarkable transformation is the result of strategic initiatives, relentless pursuit of quality, and a commitment to scientific excellence.

Two Decades of Transformation
Reflecting on Davipharm’s 20-year journey, according to Mr. Arunkumar Muthumalai – R&D Director of Davipharm, the word “transformation” encapsulates its evolution perfectly. From its early days, Davipharm has undergone significant changes to become a leading manufacturer of high-quality medicinal products.

In November 2017, Polish company Adamed Pharma acquired 70 percent of shares in Davipharm, and in April 2023, it acquired the remaining shares, becoming the sole shareholder of Davipharm. This takeover infused Davipharm with a new vision centered on producing high-quality products adhering to EU-GMP standards.

Photo: Malgorzata Adamkiewicz, MD, PhD, President of the Supervisory Board of Adamed Pharma, during her speech to Davipharm’ Team while visiting the manufacturing site in Binh Duong on 27 April 2023.

Since Adamed’s investment in Davipharm, the company was ready for a remarkable breakthrough. Davipharm’s HP Zone was certified by the Drug Administration of Vietnam (DAV) as the first high-potent drugs manufacturing area in Vietnam in 2021. The company also obtained its first EU-GMP certification in 2021, making it one of the few companies in Vietnam to do so.

These achievements underscore Davipharm’s commitment to meeting standards of high-quality allowing the international expansion. The integration with the Adamed Group played a pivotal role in this transformation. This strategy brought new expertise, resources, and a vision that aligned with Davipharm’s goals. The harmonization of operational processes, despite the challenges posed by differing organizational cultures, was a testament to the company’s dedication to excellence.

Strategies for Developing High-Quality Pharmaceutical Products from R&D
Davipharm’s R&D adheres to methods that ensure the development of high-quality and effective pharmaceutical products. Central to this strategy is the Quality by Design (QbD) methodology, which emphasizes quality from the start and enhances it at each step of the process to ensure consistent final product quality.

A thorough understanding of the reference drug product and its characterization is also crucial. This includes conducting in-vitro and in-vivo bioequivalence studies to develop generic drug products. Adhering to stringent regulatory guidelines set by agencies like the European Medicines Agency (EMA) further ensures that Davipharm’s products meet the highest standards of quality and safety.

Photo: Davipharm’s R&D Department.

Unlike many companies focusing solely on local sales, Davipharm is expanding its horizons. Ranked as the seventh-largest local pharmaceutical company in the Vietnam prescription drug market in terms of sales value, according to IQVIA data for Q1-2024, Davipharm’s strategy includes a strong emphasis on international expansion. The aim is to export high-quality products that meet stringent international standards, supported by rigorous bioequivalence studies.

To ensure adequate quality, Davipharm has a competent and experienced team familiar with constantly changing requirements. The team dedicates time to training and benefits from expert knowledge, transferring high-quality technologies from Adamed. This enhances the group’s ability to innovate and develop advanced pharmaceutical solutions that meet new market demands.

“Collaboration and continuous training are also integral to Davipharm’s R&D strategy. By fostering a culture of scientific excellence within the team, Davipharm can consistently deliver superior pharmaceutical products,” said Mr. Arunkumar Muthumalai.

A Legacy of Achievement and Future Growth
Davipharm’s journey over the past two decades is marked by significant achievements. The company’s ability to navigate market fluctuations, regulatory changes, and integration challenges highlights its strategic acumen and adaptability. Financial milestones, such as substantial investments in R&D and infrastructure, have further strengthened Davipharm’s position in the industry.

Looking ahead, Davipharm is poised to continue its trajectory of growth and innovation. The company plans to invest $12 million in CAPEX and another $12 million in R&D projects over the next five years. This ambitious plan reflects Davipharm’s commitment to developing high-value pharmaceutical products that meet the stringent requirements of regulated markets.

Photo: Davipharm’s storage capacity will have to expand to support ambitious production plans.

With the Vietnamese government’s increasing investments in healthcare and a rapidly aging population, the demand for high-quality pharmaceuticals is set to rise. Davipharm’s focus on leveraging Vietnam’s entrepreneurial spirit and digital transformation will further enhance its ability to deliver innovative solutions that improve patient care.

As stated by Mr. Michal Wieczorek – General Director of Davipharm, R&D will develop an average of 12 new products each year, and international sales are a key focus for the future. Davipharm also aims to become an Asian export hub starting in 2028.

As Davipharm celebrates its 20th anniversary, the company’s journey is a remarkable story of transformation, perseverance, and excellence. From overcoming integration challenges to pioneering innovative pharmaceutical solutions, Davipharm has consistently demonstrated its ability to adapt and thrive in a competitive industry. With a clear strategic vision and robust financial planning, Davipharm is well-positioned to achieve even greater heights in the future, solidifying its status as a leader in the pharmaceutical industry.

Check out the article on Dan Tri HERE!